The difference between SGLT2 and DPP-4 inhibitors on glucose fluctuation in patients with type 2 diabetes

Nomoto, Hiroshi; Miyoshi, Hideaki

British Journal of Research, 2017, 4(3), 21

Permalink : https://hdl.handle.net/2115/67257

このアイテムのアクセス数:926件（2026-08-18 14:36 集計）

ファイル	フォーマット	サイズ	閲覧回数	説明
BrJRes4_21	pdf	330 KB	799

アクセス権	open access
URI	https://hdl.handle.net/2115/67257
タイトル	The difference between SGLT2 and DPP-4 inhibitors on glucose fluctuation in patients with type 2 diabetes
著者	著者名 Nomoto, Hiroshi
著者	e-Rad_Researcher 30360902 著者名 Miyoshi, Hideaki
言語	英語
キーワード	Glucose fluctuation
	Dipeptidyl peptidase-4 inhibitors
	Sodium-glucose co-transporter 2 inhibitors
	Type 2 diabetes mellitus
発行日	2017
出版者	Insight Medical Publishing
収録物名	British Journal of Research
巻(号)	4(3)
ページ	21
抄録	Various oral and parental hypoglycemic agents have been developed to achieve adequate glycemic control in patients with type 2 diabetes mellitus. Because of the relatively high prevalence of cardiovascular events in this patient population, it is also necessary to minimize glucose fluctuation to prevent atherosclerotic disease. Two different types of hypoglycemic agents, dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter 2 inhibitors, appear to control glucose variability to a similar extent, but their efficacy might depend somewhat on the patient's background. To clarify which type of drug is more appropriate for use in a given patient, further investigation is needed.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
権利情報	Creative Commons Attribution 3.0 Unported
PISSN	2394-3718
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.21767/2394-3718.100021